Diabetes, Vol 40, Issue 5 527-531, Copyright © 1991 by American Diabetes Association

ARTICLES

Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition

MM Pedersen, JS Christiansen and CE Mogensen
Second University Clinic of Internal Medicine, Aarhus Kommunehospital, Denmark.

Hyperglycemia causes enhanced glucose metabolism by the polyol pathway in tissues not requiring insulin for glucose uptake. It has been suggested that the high level of aldose reductase activity may cause functional and structural abnormalities in diabetes and may be involved in the development of late complications. To elucidate the effect of an aldose reductase inhibitor (ponalrestat) on kidney function in uncomplicated insulin-dependent diabetes mellitus (IDDM), 20 normoalbuminuric IDDM patients were randomized to follow either 6 mo of treatment with ponalrestat (n = 11, mean +/- SD age 30 +/- 8 yr, diabetes duration 10 +/- 6 yr) or 6 mo of placebo (age 33 +/- 7 yr, diabetes duration 12 +/- 6 yr). The glomerular filtration rate (clearance of [125I]iothalamate) was significantly reduced from 140 +/- 18 to 129 +/- 10 ml.min-1.1.73 m-2, 2P = 0.02) in the ponalrestat-treated patients, whereas no change was seen after placebo (142 +/- 12 vs. 141 +/- 12 ml.min-1.1.73 m-2). The renal plasma flow (clearance of 131I-labeled hippuran), urinary albumin excretion rate (radioimmunoassay), fractional albumin clearance, and renal vascular resistance were unchanged in both groups. HbA1c showed a modest increase during ponalrestat (7.9 +/- 1.8 vs. 8.7 +/- 1.5%, 2P = 0.01) but was unchanged during placebo. No side effects of ponalrestat were observed. Thus, inhibition of aldose reductase may reduce the characteristic hyperfiltration in uncomplicated IDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				K. Sharma, L. Deelman, M. Madesh, B. Kurz, E. Ciccone, S. Siva, T. Hu, Y. Zhu, L. Wang, R. Henning, et al. Involvement of transforming growth factor-{beta} in regulation of calcium transients in diabetic vascular smooth muscle cells Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1258 - F1270. [Abstract] [Full Text]

				C. I. Whiteside and J. A. Dlugosz Mesangial cell protein kinase C isozyme activation in the diabetic milieu Am J Physiol Renal Physiol, June 1, 2002; 282(6): F975 - F980. [Abstract] [Full Text] [PDF]

				V. O. Shah, M. Scavini, J. Nikolic, Y. Sun, S. Vai, J. K. Griffith, R. I. Dorin, C. Stidley, M. Yacoub, D. L. Vander Jagt, et al. Z-2 Microsatellite Allele Is Linked to Increased Expression of the Aldose Reductase Gene in Diabetic Nephropathy J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2886 - 2891. [Abstract] [Full Text]

				V. O. Shah, R. I. Dorin, Y. Sun, M. Braun, and P. G. Zager Aldose Reductase Gene Expression Is Increased in Diabetic Nephropathy J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2294 - 2298. [Abstract] [Full Text] [PDF]

				C. M. Clark and D. A. Lee Prevention and Treatment of the Complications of Diabetes Mellitus N. Engl. J. Med., May 4, 1995; 332(18): 1210 - 1217. [Full Text] [PDF]